← Leaderboards
Steven R. Plump
Opalgenix, Inc.
$835,306
Attributed
$1,670,611
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $969.7K · FY2021–23$1M$750K$500K$250K$0
'21
'22
'23
Funding mix
By agency
NIH$1,670,611 · 4
By mechanism
R43$969,664 · 2
R41$374,447 · 1
R44$326,500 · 1
Top collaborators
- Senthilkumar Sadhasivam5 shared
Others in their field
Other Emerging Leaders on “Opioid Use”
- Chanza Baytop · Westat, Inc.$271,217,917
- Jeffrey Reich · Sparian Biosciences, Inc.$28,894,251
- Andrew S Huhn · Johns Hopkins University$19,514,484
- Emmanuel Aja Oga · Research Triangle Institute$17,470,090
- Suparna Goswami · Univ Of North Carolina Chapel Hill$16,919,767
- Meredith C. B. Adams · Medical College Of Wisconsin$12,691,289
Research focus
Opioid UseInnovationGenetic SignatureAdultOpioidAlgorithmsRisk PredictionAdverse OutcomeGenotypeSafetyCostOperative Surgical ProceduresCyp2d6 GeneInter-Individual VariationOpiate AddictionGenetic VariantAdverse EffectsGenetic RiskEconomic BurdenGeneticGenetic Risk FactorFutureChronicCessation Of Life
Grant awards (5)
Improving Analgesic Effectiveness and Safety with Proactive Precision Pain Management in Thoracic Surgical Patients with Lung Lesions$644,425
R43 · FY2023 · HL · contact PI
Predicting and Preventing Adverse Maternal and Child Outcomes of Opioid Use Disorder in Pregnancy$325,239
R43 · FY2023 · DA · contact PI
Reducing Opioid Use and Adverse Effects through Proactive Precision Pain Management Following Spine Surgery$326,500
R44 · FY2022 · DA · contact PI
Avoiding Adverse Opioid Outcomes with Proactive Precision Care$55,000
R41 · FY2022 · DA
Avoiding Adverse Opioid Outcomes with Proactive Precision Care$319,447
R41 · FY2021 · DA